Congress highlights: Lung Carcinoma

For congress highlights from Chicago, MEDtalks is the place to be. 

Dr. Lizza Hendriks, pulmonologist at Maastricht UMC+, selected for you her personal congress highlights for early stage and metastatic lung carcinoma. In this interview, she considers the Dutch practice.  

Through this video, you will be immediately up to date with the latest news on lung carcinoma, without having to leave your practice to do so. 

Dr. Hendriks discusses the following topics: 

Early-stage lung carcinoma

• Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
• ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
• Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816

Metastatic lung carcinoma

• Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study
• KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
• NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)